免疫学市場の2030年までの予測：薬剤クラス別、適応疾患別、用途別、地域別の世界分析

Stratistics MRCによると、世界の免疫学市場は2023年に989億3,000万米ドルを占め、2030年には1,842億1,000万米ドルに達し、CAGRは9.5%になると予測されています。

免疫学は生物医学の一分野であり、細胞、組織、臓器、分子の複雑なネットワークである免疫系の研究に焦点を当てています。免疫学は、感染症管理から自己免疫疾患やがんの治療に至るまで、医学に幅広く応用されるダイナミックで急速に発展している分野です。

英国免疫学会によると、2018年には英国で約40万人が関節リウマチに苦しんでいます。

免疫疾患の有病率の増加

遺伝的要因と世界人口の高齢化は、多くの免疫疾患の発症に重要な役割を果たしています。感染症、汚染物質、毒素などの特定の環境要因にさらされることは、免疫疾患の引き金となったり、悪化させたりする可能性があります。これらの疾患は、免疫学市場において競合環境を生み出しています。その結果、医療介入を求める患者数が増加します。そのため、免疫疾患の新興国市場での流行は、免疫学市場に多面的な影響を与え、需要、技術革新、研究開発への投資を促進しています。

厳しい規制

免疫学市場の規制は、免疫疾患関連製品の安全性、有効性、品質を確保するために設けられています。これらの規制は複雑であり、免疫医薬品の承認に向けた厳しい規制プロセスは、開発の遅延や開発コストの増大を招く可能性があります。規制上のハードルにより、市場に参入する新規治療薬の数が制限される可能性があります。このため、新規免疫療法の開拓がさらに妨げられ、市場全体のイノベーションが制限される可能性があります。

バイオテクノロジーと免疫療法の進歩

バイオテクノロジーと免疫療法の発展により、様々な免疫疾患を治療するための新たな戦略が導入されつつあります。バイオテクノロジーと免疫療法の発展により、免疫疾患の根本的な原因を対象とした特殊な治療法の開発が可能になった。さらに、個別化された治療技術も、技術の飛躍的進歩によって可能になった。免疫療法におけるこのような重要な発展と並んで、細胞治療や遺伝子治療が行われてきました。このような進歩により、免疫学市場は個別化医療戦略、標的医薬品、最先端治療法の創出によって牽引されています。

バイオシミラーとの競合

生物学的製剤の低コストの代替品であるバイオシミラーのイントロダクションは、市場に脅威をもたらす可能性があります。競合の激化は、オリジネーターである免疫学的製剤の価格圧力や市場シェアの低下につながる可能性があります。さらに、低分子化合物や遺伝子治療を含む代替療法の開発も、従来の免疫学的治療薬に対する脅威となる可能性があります。これらの新たな治療法は、新たな治療選択肢を提供し、市場シェアを獲得する可能性があります。

COVID-19の影響

COVID-19パンデミックは免疫学市場に大きな影響を与えました。パンデミックの間、免疫学研究はコビドが免疫に及ぼす影響を理解し、その深刻な影響に対処するために活発化しました。様々なCOVID-19ワクチンの成功は、世界の健康危機への対応における免疫学の重要性を浮き彫りにし、免疫学研究への投資と関心を高めることにつながった可能性があります。また、SARS-CoV-2ウイルスの新型の出現は、免疫学にスポットライトを当て続け、免疫学市場の今後の開拓に影響を与えました。

予測期間中、モノクローナル抗体分野が最大となる見込み

モノクローナル抗体セグメントは、その臨床的効率と薬剤の高い普及率から、有利な成長を遂げると推定されます。モノクローナル抗体は、抗原のような体内の特定の対象に結合するために実験室で作られるタンパク質です。モノクローナル抗体は、不要な細胞に対する免疫システムの攻撃を強化、回復、修正、模倣することができます。政府による承認も容易で、リスクも比較的低いことから、この分野はさらに拡大しています。

関節リウマチ分野は予測期間中最も高いCAGRが見込まれる

関節リウマチ分野は、高齢者人口の増加と研究開発の高まりにより、予測期間中に最も速いCAGRの成長が見込まれています。関節リウマチは、関節を侵す慢性炎症性疾患です。関節リウマチは、免疫系の調節不全に特化することで、標的治療薬や診断ツールの開拓、自己免疫疾患に対するより深い理解をもたらし、免疫学市場促進の主要要因となっています。

最大のシェアを占める地域：

北米は、医療インフラが確立されていることから、予測期間中最大の市場シェアを占めると予測されています。同地域は自己免疫疾患や慢性炎症疾患の有病率が高いです。競争の激しい北米市場では、数多くの製薬企業が免疫学関連医薬品の研究・販売に積極的に取り組んでいます。ファイザー、ジョンソン・エンド・ジョンソン、アムジェン、アッヴィ、その他の大手企業は、この地域市場で好調な業績を上げています。さらに、この地域の患者の診断率が高いことも、この分野の拡大を後押ししていると思われます。

CAGRが最も高い地域：

欧州は、自己免疫疾患の有病率の増加により、予測期間中CAGRが最も高くなると予測されています。同地域にはGenmab、Arctoris、Valo Therapeutics、BioNTechなどの主要企業が進出しています。また、ロンドンでは、英国人口の7％、400万人以上が少なくとも1つの自己免疫疾患を持っていると推定されています。同地域では、自己免疫疾患を対象にした医薬品の承認取得や上市にも力を入れています。そのため、欧州市場は消費者の健康志向の高まりとCOVID-19の流行によって牽引されています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

• 企業プロファイル
  • 追加市場参入企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データ鉱業
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• イントロダクション
• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の免疫学市場：薬剤クラス別

• イントロダクション
• 免疫抑制剤
• モノクローナル抗体
• 融合タンパク質
• ポリクローナル抗体
• 他の薬物クラス

第6章 世界の免疫学市場：疾患適応別

• イントロダクション
• 尋常性乾癬
• 関節リウマチ
• 臓器拒絶反応の予防
• 乾癬性関節炎
• 強直性脊椎炎
• 炎症性腸疾患
• その他の疾患の適応症

第7章 世界の免疫学市場：用途別

• イントロダクション
• 病院
• クリニック
• がん研究センターと機関
• その他の用途

第8章 世界の免疫学市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東とアフリカ

第9章 主要発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Novartis AG
• Eli Lilly and Company
• AbbVie Inc.
• Janssen Global Services LLC
• UCB SA
• Amgen Inc.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Aurobindo Pharma
• F. Hoffmann-La Roche Limited
• Astellas Pharma Inc.
• Merck Sharp & Dohme Corporation

List of Tables

• Table 1 Global Immunology Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 3 Global Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 4 Global Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
• Table 5 Global Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
• Table 6 Global Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
• Table 7 Global Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 8 Global Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 9 Global Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
• Table 10 Global Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
• Table 11 Global Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
• Table 12 Global Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
• Table 13 Global Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
• Table 14 Global Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
• Table 15 Global Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 16 Global Immunology Market Outlook, By Application (2021-2030) ($MN)
• Table 17 Global Immunology Market Outlook, By Hospital (2021-2030) ($MN)
• Table 18 Global Immunology Market Outlook, By Clinics (2021-2030) ($MN)
• Table 19 Global Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
• Table 20 Global Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 21 North America Immunology Market Outlook, By Country (2021-2030) ($MN)
• Table 22 North America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 23 North America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 24 North America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
• Table 25 North America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
• Table 26 North America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
• Table 27 North America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 28 North America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 29 North America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
• Table 30 North America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
• Table 31 North America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
• Table 32 North America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
• Table 33 North America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
• Table 34 North America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
• Table 35 North America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 36 North America Immunology Market Outlook, By Application (2021-2030) ($MN)
• Table 37 North America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
• Table 38 North America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
• Table 39 North America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
• Table 40 North America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 41 Europe Immunology Market Outlook, By Country (2021-2030) ($MN)
• Table 42 Europe Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 43 Europe Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 44 Europe Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
• Table 45 Europe Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
• Table 46 Europe Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
• Table 47 Europe Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 48 Europe Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 49 Europe Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
• Table 50 Europe Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
• Table 51 Europe Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
• Table 52 Europe Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
• Table 53 Europe Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
• Table 54 Europe Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
• Table 55 Europe Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 56 Europe Immunology Market Outlook, By Application (2021-2030) ($MN)
• Table 57 Europe Immunology Market Outlook, By Hospital (2021-2030) ($MN)
• Table 58 Europe Immunology Market Outlook, By Clinics (2021-2030) ($MN)
• Table 59 Europe Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
• Table 60 Europe Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 61 Asia Pacific Immunology Market Outlook, By Country (2021-2030) ($MN)
• Table 62 Asia Pacific Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 63 Asia Pacific Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 64 Asia Pacific Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
• Table 65 Asia Pacific Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
• Table 66 Asia Pacific Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
• Table 67 Asia Pacific Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 68 Asia Pacific Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 69 Asia Pacific Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
• Table 70 Asia Pacific Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
• Table 71 Asia Pacific Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
• Table 72 Asia Pacific Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
• Table 73 Asia Pacific Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
• Table 74 Asia Pacific Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
• Table 75 Asia Pacific Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 76 Asia Pacific Immunology Market Outlook, By Application (2021-2030) ($MN)
• Table 77 Asia Pacific Immunology Market Outlook, By Hospital (2021-2030) ($MN)
• Table 78 Asia Pacific Immunology Market Outlook, By Clinics (2021-2030) ($MN)
• Table 79 Asia Pacific Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
• Table 80 Asia Pacific Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 81 South America Immunology Market Outlook, By Country (2021-2030) ($MN)
• Table 82 South America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 83 South America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 84 South America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
• Table 85 South America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
• Table 86 South America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
• Table 87 South America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 88 South America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 89 South America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
• Table 90 South America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
• Table 91 South America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
• Table 92 South America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
• Table 93 South America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
• Table 94 South America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
• Table 95 South America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 96 South America Immunology Market Outlook, By Application (2021-2030) ($MN)
• Table 97 South America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
• Table 98 South America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
• Table 99 South America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
• Table 100 South America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 101 Middle East & Africa Immunology Market Outlook, By Country (2021-2030) ($MN)
• Table 102 Middle East & Africa Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 103 Middle East & Africa Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
• Table 104 Middle East & Africa Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
• Table 105 Middle East & Africa Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
• Table 106 Middle East & Africa Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
• Table 107 Middle East & Africa Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 108 Middle East & Africa Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
• Table 109 Middle East & Africa Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
• Table 110 Middle East & Africa Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
• Table 111 Middle East & Africa Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
• Table 112 Middle East & Africa Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
• Table 113 Middle East & Africa Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
• Table 114 Middle East & Africa Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
• Table 115 Middle East & Africa Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
• Table 116 Middle East & Africa Immunology Market Outlook, By Application (2021-2030) ($MN)
• Table 117 Middle East & Africa Immunology Market Outlook, By Hospital (2021-2030) ($MN)
• Table 118 Middle East & Africa Immunology Market Outlook, By Clinics (2021-2030) ($MN)
• Table 119 Middle East & Africa Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
• Table 120 Middle East & Africa Immunology Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global Immunology Market is accounted for $98.93 billion in 2023 and is expected to reach $184.21 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Immunology is the branch of biomedical science that focuses on the study of the immune system - the complex network of cells, tissues, organs, and molecules that work together to defend the body against infections and other diseases. Immunology is a dynamic and rapidly evolving field with broad applications in medicine, ranging from infectious disease management to the treatment of autoimmune conditions and cancer.

According to British Society for Immunology, in 2018, around 400,000 people in U.K are suffering with rheumatoid arthritis.

Market Dynamics:

Driver:

Increasing prevalence of immunological disorders

Genetic factors and the aging global population play a significant role in the development of many immunological disorders. Exposure to certain environmental factors, such as infections, pollutants, and toxins, may trigger or exacerbate immunological disorders. These disorders foster a competitive environment within the immunology market. It results in a larger patient population seeking medical intervention. Thereby, the increasing prevalence of immunological disorders creates a multifaceted impact on the immunology market, driving demand, innovation, and investment in research and development.

Restraint:

Strict regulations

Regulations in the immunology market are designed to ensure the safety, efficacy, and quality of products related to immunological disorders. These regulations are complex and stringent regulatory processes for the approval of immunology drugs can result in delays and increased development costs. Regulatory hurdles may limit the number of new therapies entering the market. This could further hinder the development of novel immunological therapies and limit the overall innovation in the market.

Opportunity:

Advancements in biotechnology & immunotherapy

Novel strategies for treating a range of immunological illnesses are being introduced by developments in biotechnology and immunotherapy. They make it possible to create specialised treatments that target the underlying causes of immune diseases. Moreover, personalised treatment techniques are made possible by technological breakthroughs. Alongside these important developments in immunotherapy have been cell and gene treatments. Because of these advances, the immunology market is driven by the creation of personalized medical strategies, targeted medicines, and cutting-edge treatment methods.

Threat:

Competition from biosimilars

The introduction of biosimilars, which are lower-cost alternatives to biologic drugs, can pose a threat to the market. Increased competition may lead to pricing pressures and reduced market share for originator immunology drugs. Further, the development of alternative therapies, including small molecules and gene therapies, may also pose a threat to traditional immunology drugs. These emerging therapies could offer new treatment options and potentially capture market share.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the immunology market. During the pandemic, immunology research was increased to understand the effects of covid on immunity and cope with the severe effects of the same. The success of various COVID-19 vaccines has highlighted the importance of immunology in addressing global health crises, potentially leading to increased investment and interest in immunology research. Also, the emergence of new variants of the SARS-CoV-2 virus has kept the spotlight on immunology, which influenced future developments in immunology market.

The monoclonal antibody segment is expected to be the largest during the forecast period

Themonoclonal antibody segment is estimated to have a lucrative growth, due to the clinical efficiency of the procedure and the high prevalence of drugs. Monoclonal antibodies are proteins made in the laboratory for binding to specific targets in the body, such as antigens. They can enhance, restore, modify, or mimic the immune system's attack on unwanted cells. Their easy government approvals and relatively low levels of risk, is further pushing the segment expansion.

The rheumatoid arthritis segment is expected to have the highest CAGR during the forecast period

The rheumatoid arthritis segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the growing geriatric population and rising R&D. Rheumatoid arthritis is a chronic inflammatory disorder that affects joints. Rheumatoid arthritis serves as a key driver for advancements in the immunology market by providing a specific focus on immune system deregulation, leading to the development of targeted therapies, diagnostic tools, and a deeper understanding of autoimmune diseases.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of a well-established healthcare infrastructure. The region has the high prevalence of autoimmune diseases and chronic inflammatory conditions. Numerous pharmaceutical firms are actively involved in the research and marketing of immunology medications in the fiercely competitive North American market. Pfizer, Johnson & Johnson, Amgen, AbbVie, and other significant firms are doing well in this region market. Additionally, a greater diagnosis rate among patients in the area is probably going to support the expansion of the sector.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of autoimmune disorders. The region is home for several key players such as Genmab, Arctoris, Valo Therapeutics and BioNTech. Additionally, London estimates 7% of the U.K. population, or over 4 million individuals, have at least one autoimmune disorder. The region is also making efforts to secure approvals and launch drugs targeting autoimmune conditions. Thereon, the European market is driven by growing health-consciousness among consumers and boosted by the COVID-19 pandemic.

Key players in the market:

Some of the key players profiled in the Immunology Market include Novartis AG, Eli Lilly and Company, AbbVie Inc., Janssen Global Services LLC, UCB SA, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Aurobindo Pharma, F. Hoffmann-La Roche Limited, Astellas Pharma Inc. and Merck Sharp & Dohme Corporation.

Key Developments:

In March 2023, Eli Lilly and Company received approval from the Indian regulatory agency Directorate General of Commercial Intelligence and Statistics (DGCI). This approval allowed them to launch their drug, Copellor, for the treatment of moderate-to-severe plaque psoriasis and also for psoriatic arthritis.

In March 2022, Pfizer Inc. enhanced its product offering by acquiring Arena Pharmaceuticals, a company dedicated to developing cutting-edge therapies for various immuno-inflammatory diseases.

Drug Classes Covered:

• Immunosuppressants
• Monoclonal Antibody
• Fusion Proteins
• Polyclonal Antibody
• Other Drug Classes

Disease Indications Covered:

• Plaque Psoriasis
• Rheumatoid Arthritis
• Prophylaxis of Organ Rejection
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Inflammatory Bowel Disease
• Other Disease Indications

Applications Covered:

• Hospital
• Clinics
• Cancer Research Centers & Institutions
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Immunology Market, By Drug Class

• 5.1 Introduction
• 5.2 Immunosuppressants
• 5.3 Monoclonal Antibody
• 5.4 Fusion Proteins
• 5.5 Polyclonal Antibody
• 5.6 Other Drug Classes

6 Global Immunology Market, By Disease Indication

• 6.1 Introduction
• 6.2 Plaque Psoriasis
• 6.3 Rheumatoid Arthritis
• 6.4 Prophylaxis of Organ Rejection
• 6.5 Psoriatic Arthritis
• 6.6 Ankylosing Spondylitis
• 6.7 Inflammatory Bowel Disease
• 6.8 Other Disease Indications

7 Global Immunology Market, By Application

• 7.1 Introduction
• 7.2 Hospital
• 7.3 Clinics
• 7.4 Cancer Research Centers & Institutions
• 7.5 Other Applications

8 Global Immunology Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Novartis AG
• 10.2 Eli Lilly and Company
• 10.3 AbbVie Inc.
• 10.4 Janssen Global Services LLC
• 10.5 UCB SA
• 10.6 Amgen Inc.
• 10.7 Pfizer Inc.
• 10.8 Bristol-Myers Squibb Company
• 10.9 Aurobindo Pharma
• 10.10 F. Hoffmann-La Roche Limited
• 10.11 Astellas Pharma Inc.
• 10.12 Merck Sharp & Dohme Corporation